

"Express Mail" mailing label number EL 832896577 US

Date of Deposit October 6, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Printed Name

Signature

K.S. Rhoades

K.S. Rhoades

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Yakubu-Madus, et al.)
For : SYNERGISTIC USE OF)
THIAZOLIDINEDIONES WITH GLUCAGON-)
LIKE PEPTIDE-A AND AGONISTS THEREOF TO)
TREAT METABOLIC INSTABILITY)
ASSOCIATED WITH NON-INSULIN)
DEPENDENT DIABETES)
Docket No. : X-11921A)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) for consideration by the Examiner.

As permitted by 37 C.F.R. §1.98(d), Applicants refer to application Serial No. 09/830,323, filed April 24, 2001 for copies of the listed documents.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Mark J. Stewart

Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0820

Eli Lilly and Company
Patent Division/MJS
P.O. Box 6288
Indianapolis, Indiana 46206-6288

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-11921A	Serial No
	Applicants Yakubu-Madus, et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 545,618	08/1996	Buckley et al.	
	AB	US 5, 631,224 A	05/20/97	Efendic, Suad, et al.	
	AC	US 2001/0047084	11/29/01	Knudsen, Liselotte, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number 4-Kind Code ⁵ (if known)				
	BA	WO 00/00195 A	01/06/00			
	BB	WO 99/43708	09/02/99			
	BC	WO 99/03478	01/28/99			
	BD	WO 98/57636 A	12/23/98			
	BE	WO 95/31214	11/23/95			
	BF	WO 96/20005	07/1996			
	BG	EP 0 733 644 A1	09/25/96			
	BH	EP 0 861 666 A2	09/1998			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	BOWEN L, Stein PP, Stevenson R, Shulman GI: "The Effect of CP68,722, a Thiazolidinedione Derivative, on Insulin Sensitivity in Lean and Obese Zucker Rats." Metabolism 40:1025-1030, 1991.	
	CB	CHANG Ay, Wyse BM, Gilchrist BJ, Peterson T, Diani AR: "Ciglitazone, a New Hypoglycemic Agent I: Studies in OB/OB and DB/DB Mice, Diabetic Hamsters, and Normal and Streptozotocin-diabetic Rats." Diabetes 32:830-38, 1983.	

FORM PTO 1449 (modified)	Atty. Docket No. X-11921A	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Yakubu-Madus, et al.	
	Filing Date	Group

	CC	FUJITA T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: "Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent." Diabetes <u>32</u> :804-810, 1983.	
	CD	FUJIWARA T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: "Characterization of New Oral Antidiabetic Agent CS-045 Studies in KK and OB/OB Mice and Zucker Fatty Rats." Diabetes <u>37</u> : 1549-58, 1988.	
	CE	HVDBERG A, Nielsen, T.M., Hilsted, J., Orskov, C., and Holst, J. J. "Effect of Glucagon-Like Peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man." Metabolism, Vol 43, #1 (January), 1994 pp 104-108.	
	CF	IWAMOTO Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: "Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM." Diabetes Care <u>14</u> : 1083-86, 1991.	
	CG	KRAIGEN EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH: "A Potent in Vivo Effect of Ciglitazone on Muscle Insulin Resistance Induced by High Fat Feeding of Rats." Metabolism <u>38</u> : 1089-1093, 1989.	
	CH	KUZUYA T, Iwamoto Y, Kosaka K, Yamanoushi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: "A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus." Diabetes Res. And Clin Practice.	
	CI	O'ROURKE CM, Davis J, Saltiel AR, and Cornicelli JA: "Metabolic Effects of Troglitazone in the Goto-kakizaki rat, a Non-obese and Normolipidemic Rodent Model of Non-insulin-dependent Diabetes Mellitus." Metabolism <u>46</u> : 192-198, 1997.	
	CJ	REASNER, C. A., II: "Promising New Approaches," Diabetes, Obesity Metab. (1999), 1 (Suppl. 1), pages S41-S48 XP-000971954.	
	CK	SUTER SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: "Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects." Diabetes Care <u>15</u> :193-203, 1992.	
	CL	WILLIAM GD, Delda A, Jordan WH, Gries C, Long GG, Dimarchi RD: "Subchronic Toxicity of the Thiazolidinedione, Tanabe-174 (LY 282449), in the Rat and Dog." Diabetes <u>42</u> : 1993.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-11921A	Serial No.
	Applicants Yakubu-Madus, et al.	
	Filing Date	Group

ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.